COVID-19 Vaccine
According to the CDC, everyone ages 6 months and older is eligible and encouraged to get a COVID-19 vaccine. Make sure you stay up to date with primary series doses and boosters.
The Food and Drug Administration (FDA) authorized four COVID-19 vaccines in the United States. View the Vaccine Fact Sheets below.
- Pfizer-BioNTech mRNA vaccine
- Moderna mRNA vaccine
- Novavax protein subunit vaccine
- Johnson & Johnson/Janssen (J&J) viral vector vaccine ( As of May 7, 2023, J&J COVID-19 vaccine has expired and is no longer available for use in the U.S.)
The CDC maintains a current COVID-19 vaccine schedule, including bivalent mRNA boosters. The number of doses varies by age, vaccine, and previously received COVID-19 vaccines.
Click the tabs to see CDC's vaccination schedule for your age and situation. Talk to your healthcare provider for additional guidance.
Vaccination Schedule for Most People
This section is for most people. For people who are moderately or severely immunocompromised, view the Vaccination Schedule for People who are Moderately or Severely Immunocompromised.
6 months-4 years
Unvaccinated children ages 6 months–4 years are recommended to receive either:
- 2 Moderna bivalent mRNA vaccine doses (4 or more weeks apart) or
- 3 Pfizer bivalent mRNA vaccine doses (give 2nd dose at least 3 weeks after 1st dose and give 3rd dose at least 8 weeks after 2nd dose).
Children ages 6 months–4 years who previously received only monovalent doses are recommended to receive 1 or 2 bivalent mRNA vaccine doses depending on vaccine product.
COVID-19 vaccination history
|
Authorized Bivalent Vaccine
|
Number of bivalent doses indicated
|
Total doses of vaccine
|
Interval between doses
|
Unvaccinated
|
Moderna
|
2
|
2
|
Dose 1 and dose 2: 4–8 weeks
|
Pfizer BioNTech
|
3
|
3
|
Dose 1 and dose 2: 3–8 weeks
Dose 2 and dose 3: At least 8 weeks
|
1 dose monovalent Moderna
|
Moderna
|
1
|
2
|
4-8 weeks after monovalent dose
|
2 doses monovalent Moderna
|
Moderna
|
1
|
3
|
At least 8 weeks after last monovalent dose
|
2 doses monovalent Moderna and 1 dose bivalent Moderna
|
None; previously received 1 bivalent vaccine dose
|
0
|
3
|
NA
|
1 dose monovalent Pfizer-BioNTech
|
Pfizer BioNTech
|
2
|
3
|
Dose 1: 3–8 weeks after monovalent dose
Dose 1 and dose 2: At least 8 weeks
|
2 doses monovalent Pfizer-BioNTech
|
Pfizer BioNTech
|
1
|
3
|
At least 8 weeks after last monovalent dose
|
3 doses monovalent Pfizer-BioNTech
|
Pfizer BioNTech
|
1
|
4
|
At least 8 weeks after last monovalent dose
|
2 doses monovalent Pfizer-BioNTech and 1 dose bivalent Pfizer-BioNTech
|
None; previously received 1 bivalent vaccine dose
|
0
|
3
|
NA
|
5 years
Children ages 5 years who are unvaccinated are recommended to receive 1 Pfizer or 2 Moderna bivalent mRNA vaccine doses (4 or more weeks apart). Children ages 5 years who previously received only monovalent doses are recommended to receive 1 bivalent mRNA vaccine dose.
COVID-19 vaccination history
|
Authorized Bivalent Vaccine
|
Number of bivalent doses indicated
|
Total doses of vaccine
|
Interval between doses
|
Unvaccinated
|
Moderna
|
2
|
2
|
Dose 1 and Dose 2: 4–8 weeks
|
Pfizer BioNTech
|
1
|
1
|
—
|
1 dose monovalent Moderna
|
Moderna
|
1
|
2
|
4–8 weeks after monovalent dose
|
Pfizer BioNTech
|
1
|
2
|
At least 8 weeks after monovalent dose
|
2 doses monovalent Moderna
|
Moderna
|
1
|
3
|
At least 8 weeks after last monovalent dose
|
Pfizer BioNTech
|
1
|
3
|
At least 8 weeks after last monovalent dose
|
2 doses monovalent Moderna and 1 dose bivalent mRNA
|
NA; previously received 1 bivalent vaccine dose
|
NA
|
3
|
NA
|
1 or more doses monovalent Pfizer-BioNTech
|
Pfizer-BioNTech
|
1
|
2 or more
|
At least 8 weeks after last monovalent dose
|
2 doses monovalent Pfizer-BioNTech and 1 dose bivalent Pfizer-BioNTech
|
NA; previously received 1 bivalent vaccine dose
|
NA
|
3
|
NA
|
Ever received 1 dose bivalent Pfizer-BioNTech (regardless of monovalent vaccine history)
|
NA; previously received 1 bivalent vaccine dose
|
NA
|
1 or more
|
NA
|
6-11 years
People ages 6 years and older who are unvaccinated or previously received only monovalent vaccine doses are recommended to receive 1 bivalent mRNA vaccine dose.
COVID-19 vaccination history
|
Authorized Bivalent Vaccine
|
Number of bivalent doses indicated
|
Total doses of vaccine
|
Interval between doses
|
Unvaccinated
|
Moderna
|
1
|
1
|
—
|
Pfizer BioNTech
|
1
|
1
|
—
|
1 or more doses monovalent mRNA (no doses bivalent mRNA)
|
Moderna
|
1
|
2 or more
|
At least 8 weeks after last monovalent dose
|
Pfizer BioNTech
|
1
|
2 or more
|
At least 8 weeks after last monovalent dose
|
2 or more doses monovalent mRNA and 1 dose bivalent mRNA
|
NA; previously received 1 bivalent vaccine dose
|
NA
|
3 or more
|
NA
|
Ever received 1 dose bivalent mRNA (regardless of monovalent vaccine history)
|
NA; previously received 1 bivalent vaccine dose
|
NA
|
1 or more
|
NA
|
12 years and older
People ages 12 years and older who are unvaccinated, previously received only monovalent vaccine doses, previously received 1 or more doses of Novavax, or previously received the Johnson and Johnson (Janssen) vaccine are recommended to receive 1 bivalent mRNA vaccine dose.
People ages 65 years and older have the option to receive 1 additional bivalent mRNA vaccine dose at least 4 months after the first dose of a bivalent mRNA vaccine.
COVID-19 vaccination history
|
Authorized Bivalent Vaccine†
|
Number of bivalent doses indicated
|
Total doses of vaccine
|
Interval between doses
|
Unvaccinated*
|
Moderna
|
1
|
1
|
—
|
Pfizer BioNTech
|
1
|
1
|
—
|
1 or more doses monovalent mRNA (no doses bivalent mRNA) OR
1 or more doses of Novavax vaccine (no doses bivalent mRNA) OR
1 dose of Johnson and Johnson (Janssen) vaccine (no doses bivalent mRNA)
|
Moderna
|
1
|
2 or more
|
At least 8 weeks after last monovalent dose
|
Pfizer BioNTech
|
1
|
2 or more
|
At least 8 weeks after last monovalent dose
|
1 dose of Johnson and Johnson (Janssen) vaccine and 1 or more doses monovalent vaccine
|
Moderna
|
1
|
3 or more
|
At least 8 weeks after last monovalent dose
|
Pfizer BioNTech
|
1
|
3 or more
|
At least 8 weeks after last monovalent dose
|
Younger than 65 and ever received 1 dose bivalent mRNA (regardless of monovalent vaccine history)
|
NA; previously received 1 bivalent vaccine dose
|
NA
|
1 or more
|
NA
|
65 or older and ever received 1 dose bivalent mRNA (regardless of monovalent vaccine history)
|
Moderna
|
1
|
2 or more
|
At least 4 months since last bivalent booster dose
|
Pfizer BioNTech
|
1
|
2 or more
|
At least 4 months since last bivalent booster dose
|
*People ages 12 years and older who are unable or choose not to get an updated Pfizer-BioNTech or Moderna COVID-19 vaccine can get 2-dose primary series of Novavax separated by 3–8 weeks.
†People ages 18 years and older who completed primary vaccination using any COVID-19 vaccine may receive 1 monovalent Novavax booster dose at least 6 months after completion of the primary series if they:
- Have not received any previous booster doses -AND-
- Are either:
- Unable to receive an mRNA vaccine (i.e., mRNA vaccine contraindicated or not available) -OR-
- Unwilling to receive an mRNA vaccine and would otherwise not receive a booster dose
Novavax is not authorized as a booster dose at this time for teens aged 12–17 years.
Vaccination Schedule for People who are Moderately or Severely Immunocompromised
This section is for people who are moderately or severely immunocompromised. For most people, view the Vaccination Schedule for Most People.
6 months-4 years
Unvaccinated children ages 6 months-4 years who are moderately or severely immunocompromised are recommended to receive 3 bivalent mRNA doses. Children ages 6 months-4 years who previously received only monovalent doses are recommended to receive 1 or 2 bivalent mRNA vaccine doses, depending on the number of monovalent doses already received.
COVID-19 vaccination history
|
Authorized Bivalent Vaccine
|
Number of bivalent doses indicated
|
Total doses of vaccine
|
Interval between doses
|
Unvaccinated
|
Moderna
|
3
|
3
|
Dose 1 and dose 2: 4 weeks
Dose 2 and dose 3: At least 4 weeks
|
Pfizer BioNTech
|
3
|
3
|
Dose 1 and dose 2: 3 weeks
Dose 2 and dose 3: At least 8 weeks
|
1 dose monovalent Moderna
|
Moderna
|
2
|
3
|
Dose 1: 4 weeks after monovalent dose
Dose 1 and dose 2: At least 4 weeks
|
2 doses monovalent Moderna
|
Moderna
|
1
|
3
|
At least 4 weeks after last monovalent dose
|
3 doses monovalent Moderna
|
Moderna
|
1
|
4
|
At least 8 weeks after last monovalent dose
|
3 doses monovalent Moderna and 1 dose bivalent Moderna
|
—
|
*
|
—
|
—
|
1 dose monovalent Pfizer-BioNTech
|
Pfizer BioNTech
|
2
|
3
|
Dose 1: 3 weeks after monovalent dose
Dose 1 and dose 2: At least 8 weeks
|
2 doses monovalent Pfizer-BioNTech
|
Pfizer BioNTech
|
1
|
3
|
At least 8 weeks after last monovalent dose
|
3 doses monovalent Pfizer-BioNTech
|
Pfizer BioNTech
|
1
|
4
|
At least 8 weeks after last monovalent dose
|
2 doses monovalent Pfizer-BioNTech and 1 dose bivalent Pfizer-BioNTech
|
—
|
*
|
—
|
—
|
3 doses of monovalent Pfizer-BioNTech and 1 bivalent Pfizer-BioNTech dose
|
—
|
*
|
—
|
—
|
*People ages 6 months–4 years who are moderately or severely immunocompromised have the option to receive 1 additional dose of a homologous bivalent mRNA vaccine at least 2 months following the last recommended bivalent mRNA COVID-19 vaccine dose. Further additional homologous bivalent dose(s) may be administered, informed by the clinical judgement of a healthcare provider and personal preference and circumstances. Any further additional doses should be administered at least 2 months after the last COVID-19 vaccine dose.
5 years
Unvaccinated children ages 5 years who are who are moderately or severely immunocompromised are recommended to receive 3 Pfizer or Moderna bivalent mRNA vaccine doses. Children ages 5 years who previously received only monovalent doses are recommended to receive 1 or 2 bivalent mRNA vaccine doses, depending on the number of monovalent doses already received. Children ages 5 years who previously received a bivalent mRNA vaccine dose have the option to receive 1 additional bivalent mRNA dose.
COVID-19 vaccination history
|
Authorized Bivalent Vaccine
|
Number of bivalent doses indicated
|
Total doses of vaccine
|
Interval between doses
|
Unvaccinated
|
Moderna
|
3
|
3
|
Dose 1 and dose 2: 4 weeks
Dose 2 and dose 3: At least 4 weeks
|
Pfizer BioNTech
|
3
|
3
|
Dose 1 and dose 2: 3 weeks
Dose 2 and dose 3: At least 4 weeks
|
1 dose monovalent Moderna
|
Moderna
|
2
|
3
|
Dose 1: 4 weeks after monovalent dose
Dose 1 and dose 2: At least 4 weeks
|
2 doses monovalent Moderna
|
Moderna
|
1
|
3
|
At least 4 weeks after last monovalent dose
|
3 doses monovalent Moderna
|
Moderna
|
1
|
4
|
At least 8 weeks after last monovalent dose
|
Pfizer BioNTech
|
1
|
4
|
At least 8 weeks after last monovalent dose
|
3 doses monovalent Moderna and 1 dose bivalent mRNA
|
—
|
*
|
—
|
—
|
1 dose monovalent Pfizer-BioNTech
|
Pfizer-BioNTech
|
2
|
3
|
Dose 1: 3 weeks after monovalent dose
Dose 1 and dose 2: At least 4 weeks
|
2 doses monovalent Pfizer-BioNTech
|
Pfizer-BioNTech
|
1
|
3
|
At least 4 weeks after last monovalent dose
|
3 doses monovalent Pfizer-BioNTech
|
Pfizer-BioNTech
|
1
|
4
|
At least 8 weeks after last monovalent dose
|
3 doses monovalent Pfizer-BioNTech and 1 dose bivalent Pfizer-BioNTech
|
—
|
*
|
—
|
—
|
*Children ages 5 years who are moderately or severely immunocompromised have the option to receive 1 additional dose of a bivalent mRNA vaccine at least 2 months following the last recommended bivalent mRNA COVID-19 vaccine dose. Further additional bivalent dose(s) may be administered, informed by the clinical judgement of a healthcare provider and personal preference and circumstances. Any further additional doses should be administered at least 2 months after the last COVID-19 vaccine dose. People in this age group who previously received a dose(s) of Pfizer-BioNTech vaccine are authorized to receive only Pfizer-BioNTech vaccine. Recipients who previously received Moderna vaccine are authorized to receive either bivalent mRNA vaccine.
6-11 years
Children ages 6–11 years who are moderately or severely immunocompromised who are unvaccinated or previously received only monovalent vaccine doses are recommended to receive 1 or more bivalent mRNA vaccine dose(s).
COVID-19 vaccination history
|
Authorized Bivalent Vaccine
|
Number of bivalent doses indicated
|
Total doses of vaccine
|
Interval between doses
|
Unvaccinated
|
Moderna
|
3
|
3
|
Dose 1 and dose 2: 4 weeks
Dose 2 and dose 3: At least 4 weeks
|
Pfizer BioNTech
|
3
|
3
|
Dose 1 and dose 2: 3 weeks
Dose 2 and dose 3: At least 4 weeks
|
1 dose monovalent Moderna
|
Moderna
|
2
|
3
|
Dose 1: 4 weeks after monovalent dose
Dose 1 and dose 2: At least 4 weeks
|
2 doses monovalent Moderna
|
Moderna
|
1
|
3
|
At least 4 weeks after last monovalent dose
|
3 doses monovalent Moderna
|
Moderna
|
1
|
3
|
At least 8 weeks after last monovalent dose
|
Pfizer BioNTech
|
1
|
3
|
At least 8 weeks after last monovalent dose
|
3 doses monovalent Moderna and 1 dose bivalent mRNA
|
—
|
*
|
—
|
—
|
1 dose monovalent Pfizer-BioNTech
|
Pfizer BioNTech
|
2
|
3
|
Dose 1: 3 weeks after monovalent dose
Dose 1 and dose 2: At least 4 weeks
|
2 doses monovalent Pfizer-BioNTech
|
Pfizer BioNTech
|
1
|
3
|
At least 4 weeks after last monovalent dose
|
3 doses monovalent Pfizer-BioNTech
|
Moderna
|
1
|
4
|
At least 8 weeks after last monovalent dose
|
Pfizer BioNTech
|
1
|
4
|
At least 8 weeks after last monovalent dose
|
3 doses monovalent Pfizer-BioNTech and 1 dose bivalent mRNA
|
—
|
*
|
—
|
—
|
*Children ages 6–11 years who are moderately or severely immunocompromised have the option to receive 1 additional dose of Moderna COVID-19 Vaccine or Pfizer-BioNTech COVID-19 Vaccine at least 2 months following the last recommended bivalent COVID-19 vaccine dose. Further additional dose(s) may be administered, informed by the clinical judgement of a healthcare provider and personal preference and circumstances. Any further additional doses should be administered at least 2 months after the last COVID-19 vaccine dose.
12 years and older
People ages 12 years and older who are unvaccinated, previously received only monovalent vaccine doses, previously received 1 or more doses of Novavax, or previously received the Johnson and Johnson (Janssen) vaccine are recommended to receive 1 or more bivalent mRNA vaccine dose(s).
People ages 65 years and older have the option to receive 1 additional bivalent mRNA vaccine dose at least 4 months after the first dose of a bivalent mRNA vaccine.
COVID-19 vaccination history
|
Authorized Bivalent Vaccine†
|
Number of bivalent doses indicated
|
Total doses of vaccine
|
Interval between doses
|
Unvaccinated*
|
Moderna
|
3
|
3
|
Dose 1 and dose 2: 4 weeks
Dose 2 and dose 3: At least 4 weeks
|
Pfizer BioNTech
|
3
|
3
|
Dose 1 and dose 2: 3 weeks
Dose 2 and dose 3: At least 4 weeks
|
1 dose monovalent Moderna
|
Moderna
|
2
|
3
|
Dose 1: 4 weeks after monovalent dose
Dose 1 and dose 2: At least 4 weeks
|
2 doses monovalent Moderna
|
Moderna
|
1
|
3
|
At least 4 weeks after last monovalent dose
|
3 doses monovalent Moderna
|
Moderna
|
1
|
3
|
At least 8 weeks after last monovalent dose
|
Pfizer BioNTech
|
1
|
3
|
At least 8 weeks after last monovalent dose
|
3 doses monovalent Moderna and 1 dose bivalent mRNA
|
—
|
Δ
|
—
|
—
|
1 dose monovalent Pfizer-BioNTech
|
Pfizer BioNTech
|
2
|
3
|
Dose 1: 3 weeks after monovalent dose
Dose 1 and dose 2: At least 4 weeks
|
2 doses monovalent Pfizer-BioNTech
|
Pfizer BioNTech
|
1
|
3
|
At least 4 weeks after last monovalent dose
|
3 doses monovalent Pfizer-BioNTech
|
Moderna
|
1
|
4
|
At least 8 weeks after last monovalent dose
|
Pfizer BioNTech
|
1
|
4
|
At least 8 weeks after last monovalent dose
|
3 doses monovalent Pfizer-BioNTech and 1 dose bivalent mRNA
|
—
|
Δ
|
—
|
—
|
1 or 2 doses of Novavax vaccine
|
Moderna
|
1
|
2 or 3
|
At least 8 weeks after last monovalent dose
|
Pfizer BioNTech
|
1
|
2 or 3
|
At least 8 weeks after last monovalent dose
|
1 dose of Johnson and Johnson (Janssen) vaccine (no doses bivalent mRNA)
|
Moderna
|
2
|
3
|
Dose 1: At least 4 weeks after last monovalent dose
Dose 1 and dose 2: At least 8 weeks
|
Pfizer BioNTech
|
2
|
3
|
Dose 1: At least 4 weeks after last monovalent dose
Dose 1 and dose 2: At least 8 weeks
|
1 dose of Johnson and Johnson (Janssen) and 1 dose bivalent mRNA
|
—
|
Δ
|
—
|
—
|
*People 12 years and older who are unable or choose not to get an updated Pfizer-BioNTech or Moderna COVID-19 vaccine can get 2-dose primary series of Novavax separated by 3 weeks.
†People ages 18 years and older who completed primary vaccination using any COVID-19 vaccine may receive 1 monovalent Novavax booster dose at least 6 months after completion of the primary series if they:
- Have not received any previous booster doses -AND-
- Are either:
- Unable to receive an mRNA vaccine (i.e., mRNA vaccine contraindicated or not available) -OR-
- Unwilling to receive an mRNA vaccine and would otherwise not receive a booster dose
Novavax is not authorized as a booster dose at this time for teens aged 12–17 years.
ΔPeople ages 12 years and older who are moderately or severely immunocompromised have the option to receive 1 additional dose of Moderna COVID-19 vaccine or Pfizer-BioNTech COVID-19 vaccine at least 2 months following the last recommended bivalent COVID-19 vaccine dose. Further additional dose(s) may be administered, informed by the clinical judgement of a healthcare provider and personal preference and circumstances. Any further additional doses should be administered at least 2 months after the last COVID-19 vaccine dose.
Vaccine Fact Sheets
Moderna: English, Español, አማርኛ, العربية, বাংলা, 한국어, Монгол, Pусский, 中文(简体), Tagalog, ไทย, Tiếng Việt
Pfizer-BioNTech: English, Español, አማርኛ, العربية, বাংলা, 한국어, Монгол, Pусский, 中文(简体), Tagalog, ไทย, Tiếng Việt
Novavax: English, Español, አማርኛ, العربية, বাংলা, 한국어, Монгол, Pусский, 中文(简体), ไทย, Tiếng Việt
Johnson and Johnson/Janssen (J&J): English, Español, አማርኛ, العربية, বাংলা, 한국어, Монгол, Pусский, 中文(简体), ไทย, Tiếng Việt